An injectable treatment for double chin reduction is showing promising results two years into a long-term study.
ATX-101, an injectable drug, reduces the amount of fat that develops under the chin (also called submental fat).
KYTHERA Biopharmaceuticals, maker of ATX-101, reported that 80% of participants in the study saw a significant reduction of fat under their chins after the first two years of the five-year trial.
ATX-101 is a formulation of deoxycholate, which is a natural compound that breaks down dietary fat. The procedure is done over several sessions, during which the patient gets around 50 small injections of the treatment into the chin area. The injections work to eliminate fat under the skin’s surface.